Myogen has licensed its therapy for pulmonary arterial hypertension to GlaxoSmithKline for $20 million up front and $80 million in potential milestones. Myogen's selective endothelin receptor antagonist is currently in Phase III development. Analysts noted that a $20 million up front payment for a Phase III therapy is not exceptional. Myogen also announced that financial uncertainties made it impossible to provide guidances on its performance, and its stock quickly sank more than 10 percent. Release